<DOC>
	<DOCNO>NCT02364635</DOCNO>
	<brief_summary>PRC 4016 ( Icosabutate ) - A Phase I , Single-Blind , Placebo Controlled , Single Oral Dose , Safety , Tolerability Pharmacokinetic Study Healthy Subjects Objective : - To assess safety tolerability single ascend oral dos icosabutate healthy subject - To evaluate pharmacokinetic ( PK ) parameter icosabutate healthy subject</brief_summary>
	<brief_title>Icosabutate - A Phase I , Single Oral Dose , Safety , Tolerability Pharmacokinetic Study Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>male females ethnic origin Age 1855 year BMI 18.0 33.0 kg/m2 generally good health sign informed consent male female willing use appropriate contraception recent blood donation recent blood receive high consumption alcohol high consumption tobacco subject engage heavy exercise last two week prescribe systemic topical medication take recently , supplements/remedies interfere study procedure safety medication know alter drug absorption elimination abnormal heart rate blood pressure 12lead ECG significant history drug allergy , hypersensitivity treatment ingredient ocular disorder require topical ocular therapy , recent allergic eye disease significant medical history physical finding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Phase I pharmacokinetics safety study</keyword>
</DOC>